Phillip M. Galbo

1.9k total citations · 1 hit paper
29 papers, 960 citations indexed

About

Phillip M. Galbo is a scholar working on Molecular Biology, Immunology and Oncology. According to data from OpenAlex, Phillip M. Galbo has authored 29 papers receiving a total of 960 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 10 papers in Immunology and 7 papers in Oncology. Recurrent topics in Phillip M. Galbo's work include Immune Cell Function and Interaction (4 papers), Immunotherapy and Immune Responses (4 papers) and T-cell and B-cell Immunology (4 papers). Phillip M. Galbo is often cited by papers focused on Immune Cell Function and Interaction (4 papers), Immunotherapy and Immune Responses (4 papers) and T-cell and B-cell Immunology (4 papers). Phillip M. Galbo collaborates with scholars based in United States, Japan and Canada. Phillip M. Galbo's co-authors include Deyou Zheng, Xingxing Zang, Frederick L. Altice, Liana Fraenkel, Alex Dubov, Wei Yao, Michael J. Ciesielski, Robert A. Fenstermaker, Mou Peng and Sheila Figel and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nucleic Acids Research and Journal of Clinical Investigation.

In The Last Decade

Phillip M. Galbo

28 papers receiving 955 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Molecular Features of Cancer-associated Fibroblast Subtypes and their Implication on Cancer Pathogenesis, Prognosis, and Immunotherapy Resistance

2021 225 citations Phillip M. Galbo, Xingxing Zang et al. Clinical Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Phillip M. Galbo United States	17	392	325	271	165	149	29	960
Michelle Lockley United Kingdom	23	532 1.4×	692 2.1×	395 1.5×	202 1.2×	43 0.3×	64	1.7k
Merav Bar United States	20	606 1.5×	893 2.7×	361 1.3×	253 1.5×	27 0.2×	50	1.8k
Beth Isaac United States	9	499 1.3×	391 1.2×	137 0.5×	108 0.7×	50 0.3×	24	1.1k
Dariusz Iżycki Poland	20	390 1.0×	295 0.9×	210 0.8×	159 1.0×	13 0.1×	53	1.2k
Jennifer L. Hope United States	14	344 0.9×	170 0.5×	417 1.5×	229 1.4×	41 0.3×	28	897
William Weber United States	17	471 1.2×	237 0.7×	176 0.6×	161 1.0×	98 0.7×	33	1.0k
Anna Fialová Czechia	14	269 0.7×	656 2.0×	721 2.7×	101 0.6×	61 0.4×	33	1.2k
Hongxiang Wang China	18	487 1.2×	88 0.3×	167 0.6×	296 1.8×	30 0.2×	59	968
Guanxin Shen China	16	608 1.6×	153 0.5×	243 0.9×	259 1.6×	95 0.6×	42	1.1k
Karen Parker United States	13	352 0.9×	300 0.9×	289 1.1×	47 0.3×	24 0.2×	23	1.2k

Countries citing papers authored by Phillip M. Galbo

Since Specialization

Citations

This map shows the geographic impact of Phillip M. Galbo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Phillip M. Galbo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Phillip M. Galbo more than expected).

Fields of papers citing papers by Phillip M. Galbo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Phillip M. Galbo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Phillip M. Galbo. The network helps show where Phillip M. Galbo may publish in the future.

Co-authorship network of co-authors of Phillip M. Galbo

This figure shows the co-authorship network connecting the top 25 collaborators of Phillip M. Galbo. A scholar is included among the top collaborators of Phillip M. Galbo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Phillip M. Galbo. Phillip M. Galbo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Galbo, Phillip M., et al.. (2025). A Comprehensive Guide to Achieving New York State Clinical Laboratory Evaluation Program Approval for Next-Generation Sequencing Assays. Journal of Molecular Diagnostics. 27(6). 485–501. 2 indexed citations

Ronnett, Brigitte M., Lisa Haley, Aparna Pallavajjala, et al.. (2025). Clinicopathologic and Molecular Analysis of Malignant Neoplasms With Yolk Sac Tumor Differentiation in Women 40 Years of Age and Older. The American Journal of Surgical Pathology. 49(7). 686–700.

Galbo, Phillip M., Joanne Xiu, Soma Sengupta, et al.. (2024). VISTA Emerges as a Promising Target against Immune Evasion Mechanisms in Medulloblastoma. Cancers. 16(15). 2629–2629. 4 indexed citations

Galbo, Phillip M., Wei Yao, Wei Cui, et al.. (2024). TOP CAR with TMIGD2 as a safe and effective costimulatory domain in CAR cells treating human solid tumors. Science Advances. 10(19). eadk1857–eadk1857. 8 indexed citations

Galbo, Phillip M., Kartik Chandran, Yinghao Wu, et al.. (2024). Fine-tuning spatial-temporal dynamics and surface receptor expression support plasma cell-intrinsic longevity. eLife. 12. 2 indexed citations

Wang, Hao, R. Alejandro Sica, Gurbakhash Kaur, et al.. (2024). TMIGD2 is an orchestrator and therapeutic target on human acute myeloid leukemia stem cells. Nature Communications. 15(1). 11–11. 32 indexed citations

Galbo, Phillip M., Kartik Chandran, Yinghao Wu, et al.. (2023). Fine-tuning spatial-temporal dynamics and surface receptor expression support plasma cell-intrinsic longevity. eLife. 12. 7 indexed citations

Galbo, Phillip M., Anne Tranberg Madsen, Yang Liu, et al.. (2023). Functional Contribution and Clinical Implication of Cancer-Associated Fibroblasts in Glioblastoma. Clinical Cancer Research. 30(4). 865–876. 40 indexed citations

Cui, Jihong, Chi Zhang, Ji‐Eun Lee, et al.. (2023). MLL3 loss drives metastasis by promoting a hybrid epithelial–mesenchymal transition state. Nature Cell Biology. 25(1). 145–158. 35 indexed citations

10.

Picarda, Élodie, Phillip M. Galbo, Haihong Zong, et al.. (2022). The immune checkpoint B7-H3 (CD276) regulates adipocyte progenitor metabolism and obesity development. Science Advances. 8(17). eabm7012–eabm7012. 20 indexed citations

11.

Galbo, Phillip M., Ameya Kulkarni, Atefeh Taherian Fard, et al.. (2022). Redox signaling by glutathione peroxidase 2 links vascular modulation to metabolic plasticity of breast cancer. Proceedings of the National Academy of Sciences. 119(8). 37 indexed citations

12.

Akhmetzyanova, Ilseyar, Phillip M. Galbo, Anastasia N. Tikhonova, et al.. (2021). Tissue-resident macrophages promote early dissemination of multiple myeloma via IL-6 and TNFα. Blood Advances. 5(18). 3592–3608. 25 indexed citations

13.

Galbo, Phillip M., Xingxing Zang, & Deyou Zheng. (2021). Molecular Features of Cancer-associated Fibroblast Subtypes and their Implication on Cancer Pathogenesis, Prognosis, and Immunotherapy Resistance. Clinical Cancer Research. 27(9). 2636–2647. 225 indexed citations breakdown →

14.

Zhao, Lianzhong, Pengcheng Zhang, Phillip M. Galbo, et al.. (2021). Transcription factor MEF2D is required for the maintenance of MLL-rearranged acute myeloid leukemia. Blood Advances. 5(22). 4727–4740. 16 indexed citations

15.

Yao, Wei, Xiaoxin Ren, Phillip M. Galbo, et al.. (2021). KIR3DL3-HHLA2 is a human immunosuppressive pathway and a therapeutic target. Science Immunology. 6(61). 65 indexed citations

16.

Galbo, Phillip M., et al.. (2021). Polycomb repressive complex 2 in adult hair follicle stem cells is dispensable for hair regeneration. PLoS Genetics. 17(12). e1009948–e1009948. 6 indexed citations

17.

Pu, Hong, José Silva, Idan Cohen, et al.. (2021). UV-induced reduction in Polycomb repression promotes epidermal pigmentation. Developmental Cell. 56(18). 2547–2561.e8. 15 indexed citations

18.

Xu, Chenxi, Yi‐Hsuan Tsai, Phillip M. Galbo, et al.. (2021). Cistrome analysis of YY1 uncovers a regulatory axis of YY1:BRD2/4-PFKP during tumorigenesis of advanced prostate cancer. Nucleic Acids Research. 49(9). 4971–4988. 35 indexed citations

19.

Burkhart, Deborah L., Katherine L. Morel, Kristine M. Wadosky, et al.. (2020). Evidence that EZH2 Deregulation is an Actionable Therapeutic Target for Prevention of Prostate Cancer. Cancer Prevention Research. 13(12). 979–988. 4 indexed citations

20.

Fenstermaker, Robert A., Sheila Figel, Jingxin Qiu, et al.. (2018). Survivin Monoclonal Antibodies Detect Survivin Cell Surface Expression and Inhibit Tumor Growth In Vivo. Clinical Cancer Research. 24(11). 2642–2652. 35 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact